Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

SERRETTA, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.452
EU - Europa 6.696
AS - Asia 1.691
AF - Africa 51
OC - Oceania 24
SA - Sud America 15
Continente sconosciuto - Info sul continente non disponibili 7
Totale 20.936
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.435
IT - Italia 1.773
CN - Cina 1.117
FI - Finlandia 1.011
UA - Ucraina 964
RU - Federazione Russa 663
IE - Irlanda 569
DE - Germania 547
SE - Svezia 359
GB - Regno Unito 334
SG - Singapore 314
FR - Francia 148
BE - Belgio 96
RO - Romania 93
IN - India 77
KR - Corea 59
CI - Costa d'Avorio 38
CH - Svizzera 35
NL - Olanda 30
HK - Hong Kong 20
JP - Giappone 20
AU - Australia 19
CA - Canada 14
CZ - Repubblica Ceca 14
TR - Turchia 13
PL - Polonia 12
IR - Iran 11
AT - Austria 10
GR - Grecia 10
ES - Italia 9
IL - Israele 8
EU - Europa 6
ID - Indonesia 6
KW - Kuwait 6
LB - Libano 5
NZ - Nuova Zelanda 5
TW - Taiwan 5
UZ - Uzbekistan 5
AR - Argentina 4
AL - Albania 3
BD - Bangladesh 3
BG - Bulgaria 3
BR - Brasile 3
CL - Cile 3
CO - Colombia 3
MX - Messico 3
PK - Pakistan 3
PT - Portogallo 3
SA - Arabia Saudita 3
SD - Sudan 3
ZA - Sudafrica 3
CM - Camerun 2
DK - Danimarca 2
EC - Ecuador 2
EG - Egitto 2
GE - Georgia 2
MD - Moldavia 2
MN - Mongolia 2
PH - Filippine 2
RS - Serbia 2
TH - Thailandia 2
VN - Vietnam 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BH - Bahrain 1
BT - Bhutan 1
EE - Estonia 1
KH - Cambogia 1
LU - Lussemburgo 1
LY - Libia 1
ME - Montenegro 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
OM - Oman 1
TN - Tunisia 1
Totale 20.936
Salva come PNG Salva come JPEG
Città #
Fairfield 1.631
Ashburn 1.149
Chandler 1.084
Woodbridge 867
Wilmington 821
Ann Arbor 759
Houston 680
Seattle 625
Dublin 567
Jacksonville 526
Cambridge 515
Medford 413
Nanjing 275
Des Moines 267
Princeton 265
Singapore 224
Altamura 171
Palermo 171
Boardman 149
Tulsa 148
Lawrence 137
New York 126
Dearborn 122
Beijing 112
Nanchang 108
San Diego 106
Brussels 95
Shenyang 91
Milan 78
Hebei 73
Helsinki 70
Changsha 63
Jiaxing 62
Ludwigshafen am Rhein 61
Tianjin 60
Seongnam 46
Jinan 43
Kumar 43
Saint Petersburg 43
Santa Clara 39
Verona 39
Abidjan 38
Redwood City 37
Bremen 34
Venice 34
Nave 33
London 31
Auburn Hills 30
Zhengzhou 28
Falls Church 26
Rome 26
San Mateo 26
Ningbo 25
San Paolo di Civitate 25
Guangzhou 24
Washington 22
Lanzhou 19
Taizhou 18
Hangzhou 17
Kunming 17
Napoli 17
Norwalk 16
Dallas 15
Düsseldorf 14
Taiyuan 13
Edinburgh 12
Orange 12
Hefei 11
Los Angeles 11
Mountain View 11
Munich 11
Nuremberg 11
Pune 11
Catania 10
Chicago 10
Haikou 10
Indiana 10
Brno 9
Central District 9
Paris 9
Phoenix 9
Redmond 9
Tokyo 8
Bologna 7
Den Haag 7
Kilburn 7
San Francisco 7
Seoul 7
Springfield 7
Sydney 7
Yellow Springs 7
Amsterdam 6
Berlin 6
Central 6
Moscow 6
New Bedfont 6
Ozieri 6
Sandston 6
Stockholm 6
Tehran 6
Totale 13.802
Salva come PNG Salva come JPEG
Nome #
S9-Fibronectin, EGF-R, HB-EGF:biomarkers of urothelial damage during intravesical adjuvant therapy? 512
Characterization of human infiltrating and circulating gamma-delta t cells in prostate cancer 215
Manuale di Urologia e Andrologia. Capitolo 1: Anatomia dell'apparato genito-urinario 190
Clinical and biochemical markers of visceral adipose tissue activity: Body mass index, visceral adiposity index, leptin, adiponectin, and matrix metalloproteinase-3. Correlation with Gleason patterns 4 and 5 at prostate biopsy 188
Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. 182
Whatsapp messenger as a tool for the multidisciplinary management in everyday clinical practice 177
Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy 172
Cytokine gene expression in the tunica albuginea 
of patients with Peyronie’s disease. Pilot study with 
a control group 171
Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study 164
Drinking water source and cigarette smoking in transitional cell carcinoma of the bladder. 154
A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. 154
Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma 153
Segmental resection of distal ureter with termino-terminal ureteric anastomosis vs bladder cuff removal and ureteric re-implantation for upper tract urothelial carcinoma: results of a multicentre study 147
Sarcomatoid carcinoma of urinary bladder: Immunohistochemical study of an uncommon case 143
Preliminary report of a multicentric study on environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder 142
Carcinoma uroteliale in cisti pielogena 138
Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes 138
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder 137
A phase I-II study on intravesical Gemcitabine in superficial bladder papillary tumors 135
Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials? 135
PROSPECTIVE, RANDOMIZED, CROSSOVER COMPARISON OF SUBLINGUAL APOMORPHINE (3 mg) WITH ORAL SILDENAFIL (50 mg) FOR MALE ERECTILE DYSFUNCTION 134
PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients 132
Modificazioni del PSA dopo terapia antibiotica in pazienti candidati alla biopsia prostatica. 130
Multiplicity and history have a detrimental effect on survival in patients with T1G3 bladder tumors selected for conservative treatment. 130
Cytokines gene expression in the tunica albuginea of patients with Peyronie’s disease. Pilot study with a control group 129
Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder: Phase I-II study on marker lesions 126
Il carcinoma prostatico in Calabria e Sicilia. 125
Clinical implications of a rare renal entity: Pleomorphic Hyalinizing Angiectatic Tumor (PHAT) 124
Although rare, severe complications following intravesical bacillus Calmette-Guerin treatment should not be overlooked! 121
Re: Urinary pH is Highly Associated With Tumor Recurrence During Intravesical Mitomycin C Therapy for Nonmuscle Invasive Bladder Tumor 118
The activity of intravesical hyaluronic acid and chondroitin sulfate administration on urothelial gene expression. Preliminary results on the epidermal growth factor receptor and fibronectin gene expression evaluated in bladder washings of patients affected by non muscle-invasive bladder cancer 118
Mitomycin C from birth to adulthood 117
T1HG Bladder Tumours: So Many Papers, Do We Need Them? Yes, We Do! 116
Prognostic Factors and Risk Groups in T1G3 Non–Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Gue´ rin: Results of a retrospective Multicenter Study of 2451 Patients 116
Distribution of smoking, water resource and other environmental factors in patients affected by superficial bladder cancer 114
PSA and second-line therapy of hormone refractory prostate carcinoma 113
Does Exist A Correlation Between BMI and Gleason Patterns 4 and 5 At Prostate Biopsy? 111
The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer 111
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer 111
The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin 111
Cytokines gene expression in the tunica albuginea in patients with Peyronie’s disease. Pilot study with a control group 109
PROGNOSTIC FACTORS AND RISK GROUPS IN T1G3 PATIENTS INITIALLY TREATED WITH BCG: RESULTS OF A MULTICENTER RETROSPECTIVE SERIES IN 2530 PATIENTS 108
A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. 108
WHATSAPP MESSENGER AS A REAL-TIME TOOL FOR A LONG-DISTANCE ACTIVITY OF A MULTIDISCIPLINARY 108
Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression 108
Intravesical gemcitabine in superficial bladder tumours preliminary results of a phase I-II study 107
Genitourinary Symptoms-Patient Help-Seeking and General Practitioner Management: An Outpatient Based Survey at a Tertiary Hospital in Southern Italy 107
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer 107
INTRAVESICAL GEMCITABINE IN SUPERFICIAL BLADDER TUMOURS.RESULTS OF A PHASE I-II STUDY 106
Studio pilota sul valore predittivo dei livelli plasmatici di 9 fattori angiogenetici nella selezione di pazienti candidati alla biopsia prostatica 106
Segmental ureterectomy vs. radical nephroureterectomy for ureteral carcinoma in patients with a preoperative glomerular filtration rate less than 90 ml/min/1.73 m2: A multicenter study 106
High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study 105
Analisi preliminare dei fattori demografici ed eziopatogenetici in pazienti affetti da carcinoma vescicale a medio rischio di recidiva 104
The clinical value of PSA increase during intravesical adjuvant therapy for nonmuscle-invasive bladder cancer. 104
Moderate hypofractionated helical tomotherapy for prostate cancer in a cohort of older patients: a mono-institutional report of toxicity and clinical outcomes 104
Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital 104
Variability in the Performance of Nuclear Matrix Protein 22 for the Detection of Bladder Cancer 102
Cigarette smoking and drinking water source: Correlation with clinical features and pathology of superficial bladder carcinoma. 102
Impact of stage migration on bladder cancer: A slow but steady improvement in the long term survival rates after radical cystectomy in the last 25 years 102
The fate of patients with locally advanced bladder cancer treated conservatively with neoadjuvant chemotherapy, extensive transurethral resection and radiotherapy: 10-year experience 102
Ruolo prognostico della p53 nel tumore vescicale superficiale. Correlazione con recidiva e progressione – 101
TERAPIA CONSERVATIVA DELL'UROTELIOMA VESCICALE T1G3. RISULTATI SU 235 PAZIENTI 101
Environmental factors in superficial bladder cancer. Preliminary report of a prospective study 101
Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the vesical antiblastic therapy Italian study 101
Clinical pitfalls in diagnosis of nonmuscle-invasive bladder cancer 101
The Clinical Use of Statistical Permutation Test Methodology: A Tool for Identifying Predictive Variables of Outcome 100
Modified Glasgow prognostic score is associated with risk of recurrence in bladder cancer patients after radical Cystectomy: A multicenter experience 100
POSITIVITA’ DELL’NMP22 E NEGATIVITA’ CISTOSCOPICA E CITOLOGICA. QUALE SIGNIFICATO ATTRIBUIRE? 99
Cigarette Smoking Status at Diagnosis and Recurrence in Intermediate-risk Nonemuscle-invasive Bladder Carcinoma 99
Postoperative nomogram for invasive bladder cancer: Does it really work? A multicenter cohort study 99
Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer 99
Valore clinico della riduzione del PSA in soggetti candidati all’agobiopsia prostatica 98
Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer 98
PROSTATA (PROSTATITI, IPERTROFIA PROSTATICA, CANCRO DELLA PROSTATA) 97
Salvage Therapy With Oral Metronomic Cyclophosphamide and Methotrexate for Castration refractory Metastatic Adenocarcinoma of the Prostate Resistant to Docetaxel 97
Significato clinico della positività della NMP22 in pazienti in follow-up per carcinoma vescicale superficiale. Risultati a lungo termine 96
Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?--a phase II study 96
CORSO Carcinoma vescicale non muscolo invasivo : qualità del trattamento endoscopico 95
Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer 94
Attività lavorativa e fattori di rischio ambientale in pazienti affetti da carcinoma vescicale superficiale. 94
Correlation between clinical response and urinary interleukin levels using different doses and intravesical administration schedules of interferon-alpha-2b combined with epirubicin: a pilot study 94
Studio randomizzato sul ruolo del mantenimento nella chemioprofilassi endovescicale precoce dopo TUR con Epirubicina. XVI Congresso Nazionale Società Italiana di Urologia Oncologica. 30 Novembre - 3 Dicembre 2006. Arch. Ital. Urol. Androl. vol. , pp. 71. ISBN/ISSN: 1124-3562. 93
TUR AND ADJUVANT INTRAVESCICAL CHEMOTHERAPY IN T1G3 BLADDER TUMORS. RECURRENCE, PROGRESSION AND SURVIVAL IN 137 SELECTED PATIENTS FOLLOWED UP TO 20 YEARS. 92
Fumo, risorsa idrica ed altri fattori di rischio nel carcinoma vescicale superficiale 92
Correlation between chronic prostatitis syndrome and pelvic venous disease. A survey of 2554 urologic outpatients 92
Does Smoking Cessation at Primary Diagnosis Reduce the Recurrence Risk of Nonmuscle-Invasive Bladder Cancer? Results of a Prospective Study 92
How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency? 92
Intravesical gemcitabine is superficial bladder tumours. Results of a phase I-II study 91
Environmental factors in superficial bladder cancer. Preliminary report of a prospective study 91
Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma 91
Single dose prulifloxacina can improve BCG tollerability 91
Correlation between BMI and the pathological features of prostate cancer at biopsy 91
Editorial Comment to Infectious aortic aneurysms occurring 1 year after bacillus Calmette–Guérin bladder instillation therapy 91
Fumo di sigaretta e risorsa idrica in pazienti affetti da carcinoma vescicale superficiale. XV Congresso Nazionale SIUro, Giardini Naxos 3-6 novembre 2005. 1. 90
Studio di phase II: Docetaxel settimanale come seconda linea chemioterapia nel carcinoma prostatico avanzato. 90
Chemioterapia adiuvante e fattori di rischio ambientale nel carcinoma vescicale superficiale a medio rischio di recidiva. Uno studio prospettico randomizzato del Gruppo Studio Tumori Urologici (GSTU). 89
Uso degli alfa-bloccanti nell'ipertrofia prostatica benigna: il problema della "floppy irisi syndrome". Risultati di uno studio caso-controllo per la valutazione del rischio pre-operatorio con la misura del diametro pupillare 89
Peyronie’s disease: Cytokines genes expression in tunica albuginea 89
Fibronectin (FN), epidermal growth factor-receptor (EGF-R) and heparin-binding epidermal growth factor-like (HB-EGF) urinary expressions and topical toxicity of adjuvant intravesical therapy for non muscle invasive bladder cancer (NMI-BC) 89
RECURRENCE AND PROGRESSION ACCORDING TO STAGE AT RE-TUR IN T1G3 BLADDER CANCER PATIENTS TREATED WITH BCG: NOT AS BAD AS PREVIOUSLY THOUGHT 89
Totale 11.847
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.377
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.377
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.117 0 0 297 461 518 650 526 303 495 289 362 216
2020/20212.847 134 243 190 257 253 163 268 149 317 223 277 373
2021/20222.688 126 575 61 140 150 115 73 142 332 331 108 535
2022/20233.773 418 549 89 334 406 498 229 238 801 21 137 53
2023/20241.744 71 239 171 180 153 358 153 126 11 21 75 186
2024/2025432 138 218 76 0 0 0 0 0 0 0 0 0
Totale 21.758